Shares of Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) shot up 13.1% on Friday . The stock traded as high as $2.1550 and last traded at $2.1550. 100 shares traded hands during trading, a decline of 13% from the average session volume of 116 shares. The stock had previously closed at $1.9050.
Innate Pharma Price Performance
The stock’s 50-day moving average price is $2.00 and its 200-day moving average price is $1.84.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Featured Articles
- Five stocks we like better than Innate Pharma
- The Most Important Warren Buffett Stock for Investors: His Own
- Nike Beats on Earnings But Struggles in China and Faces Tariffs
- Dividend Capture Strategy: What You Need to Know
- Is the AI Boom a Bubble? These 2 Dividend Stocks Say No
- Growth Stocks: What They Are, What They Are Not
- 4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
